AIFM3
Apoptosis-inducing factor 3
Also known as: AIFL, AIFM3_HUMAN, FLJ30473
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96NN9
- Gene
- AIFM3
- Ensembl
- ENSG00000183773
- Chromosome
- 22
- Canonical length
- 605 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Mitochondria
OverviewNCBI Gene
Predicted to enable oxidoreductase activity, acting on NAD(P)H. Involved in execution phase of apoptosis. Located in cytosol; endoplasmic reticulum; and mitochondrial inner membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
605 residues, UniProt reviewed canonical sequence.
>Q96NN9|AIFM3
1 MGGCFSKPKP VELKIEVVLP EKERGKEELS ASGKGSPRAY QGNGTARHFH TEERLSTPHP
61 YPSPQDCVEA AVCHVKDLEN GQMREVELGW GKVLLVKDNG EFHALGHKCP HYGAPLVKGV
121 LSRGRVRCPW HGACFNISTG DLEDFPGLDS LHKFQVKIEK EKVYVRASKQ ALQLQRRTKV
181 MAKCISPSAG YSSSTNVLIV GAGAAGLVCA ETLRQEGFSD RIVLCTLDRH LPYDRPKLSK
241 SLDTQPEQLA LRPKEFFRAY GIEVLTEAQV VTVDVRTKKV VFKDGFKLEY SKLLLAPGSS
301 PKTLSCKGKE VENVFTIRTP EDANRVVRLA RGRNVVVVGA GFLGMEVAAY LTEKAHSVSV
361 VELEETPFRR FLGERVGRAL MKMFENNRVK FYMQTEVSEL RGQEGKLKEV VLKSSKVVRA
421 DVCVVGIGAV PATGFLRQSG IGLDSRGFIP VNKMMQTNVP GVFAAGDAVT FPLAWRNNRK
481 VNIPHWQMAH AQGRVAAQNM LAQEAEMSTV PYLWTAMFGK SLRYAGYGEG FDDVIIQGDL
541 EELKFVAFYT KGDEVIAVAS MNYDPIVSKV AEVLASGRAI RKREVELFVL HSKTGDMSWL
601 TGKGSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AIFM3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 137 nTPM
Expression across tissuesHPA
Tissue
- choroid plexus: 137 nTPM
- cerebral cortex: 34 nTPM
- cerebellum: 29 nTPM
- amygdala: 22 nTPM
- colon: 20 nTPM
- midbrain: 20 nTPM
Single-cell type
- astrocytes: 16 nCPM
- retinal pigment epithelial cells: 13 nCPM
- choroid plexus epithelial cells: 9.6 nCPM
- colonocytes: 8.7 nCPM
- enteric stem cells: 5.5 nCPM
- bergmann glia: 5.2 nCPM
Immune cell
- intermediate monocyte: 3 nTPM
- myeloid DC: 1.9 nTPM
- non-classical monocyte: 1.9 nTPM
- classical monocyte: 1.1 nTPM
- total PBMC: 0.5 nTPM
- memory B-cell: 0.1 nTPM
Brain region
- choroid plexus: 280 nTPM
- thalamus: 141 nTPM
- cerebral cortex: 100 nTPM
- medulla oblongata: 90 nTPM
- pons: 85 nTPM
- midbrain: 84 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.99
- gnomAD pLI
- 0
- gnomAD missense Z
- 1
- DepMap mean gene effect
- -0.09
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FAD/NAD-linked reductase, dimerisation domain superfamily
- Rieske [2Fe-2S] iron-sulphur domain
- FAD/NAD(P)-binding domain
- FAD/NAD(P)-binding domain superfamily
- Rieske [2Fe-2S] iron-sulphur domain superfamily
- FAD-dependent Oxidoreductases and Apoptosis Regulators
- Rieske [2Fe-2S] domain
- Pyridine nucleotide-disulphide oxidoreductase
- Reductase, C-terminal
- Reductase C-terminal
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AIFM3 as an antibody target. Whether an autoantibody or antibody against AIFM3 could matter depends on whether native AIFM3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AIFM3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label AIFM3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...